5-Amino-1MQ: New Perspectives for Metabolic Research
Dr. Sieglinde Klaus
Scientific Editorial Team · Bergdorf Bioscience
Table of Contents
- 01What is 5-Amino-1MQ, and why is it of research interest?
- 02How does NNMT connect nicotinamide, NAD+, and methyl-group metabolism?
- 03What positive signals have cell studies shown with 5-Amino-1MQ?
- 04What was observed in mice for body weight and adipose tissue?
- 05Which additional metabolic findings add to the picture?
- 06Why is 5-Amino-1MQ also of interest in muscle research?
- 07What can be learned from the different genetic models?
- 08What is known about absorption and half-life?
- 09How does this approach differ from NMN, NR, and mitochondrial peptides?
- 10How can the findings be interpreted positively and rigorously at the same time?
- 11Which questions about 5-Amino-1MQ are frequently asked?
- Is 5-Amino-1MQ a peptide?
- Are there indications of an effect?
- Is 5-Amino-1MQ the same as NMN or NR?
- Is there a scientifically established dose for humans?
- Where can readers find further information about this research compound?
- 12Which original studies inform this article?
5-Amino-1MQ is a small molecule that inhibits the metabolic enzyme NNMT. Cell and animal studies have observed interesting effects on adipose tissue, metabolic markers, and regeneration in ageing muscle. This makes the compound a promising research tool. How does this potential arise, which findings support it, and which questions guide the research forward?
The story of 5-Amino-1MQ begins at an intersection in cellular metabolism: how cells use nicotinamide and methyl groups. Influencing that allocation could also affect processes related to energy metabolism and tissue function. The following overview connects the mechanism with the models that have actually been studied. It explains why early positive findings have scientific value without treating them as established benefits in humans.
What is 5-Amino-1MQ, and why is it of research interest?
The name refers to 5-amino-1-methylquinolinium, a low-molecular-weight compound in the quinolinium group. Unlike a peptide, it is not made of a chain of amino acids. Its occasional placement among “research peptides” therefore describes the setting in which the compound is discussed rather than its chemical identity.
Its target is nicotinamide N-methyltransferase, or NNMT. This enzyme attracted attention because its activity is connected to metabolic processes in adipose tissue and other organs. In a foundational 2014 study, reduced NNMT expression protected mice from diet-induced weight gain. That finding prompted the question of whether the same target could be studied with small molecules. Kraus et al., 2014
Subsequent medicinal-chemistry work identified quinolinium compounds as useful starting structures for NNMT inhibitors. A structure-activity study described members of this class with low-micromolar enzyme inhibition. Measurements of this kind help connect chemical properties and target binding in a systematic way. Neelakantan et al., 2017
For readers, this development story is useful because 5-Amino-1MQ rests on a specific biological target hypothesis. Its research relevance comes from a testable mechanism and measurable responses to it. That is a firmer basis than a superficial resemblance to a familiar supplement or placement in a popular product category.
How does NNMT connect nicotinamide, NAD+, and methyl-group metabolism?
NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide. This produces 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Nicotinamide is also needed to rebuild NAD+. NAD+ is a coenzyme involved in fundamental reactions of energy metabolism.
NNMT therefore connects two areas of interest: the use of nicotinamide and the consumption of the methyl donor SAM. The research hypothesis is that inhibiting the enzyme can influence this allocation. Less flux through NNMT could leave nicotinamide available for NAD+ recycling and SAM available for other reactions. Genetic work by Kraus and colleagues also linked NNMT to polyamine metabolism and energy expenditure in the models studied. Kraus et al., 2014
NNMT can be understood as a branch point in a metabolic network. Changing the flow at that point can also change neighbouring pathways. The consequences depend on the tissue under study and its physiological state. A metabolic network does not behave like a single on-off switch.
This connection is what makes the approach interesting: NNMT inhibition acts on the use of existing metabolic building blocks. It does not supply an NAD+ precursor itself. That is why 5-Amino-1MQ and NAD+ precursors such as NMN or NR represent different research approaches, even when they appear in similar discussions.
What positive signals have cell studies shown with 5-Amino-1MQ?
Cell studies first make it possible to address a basic question: does an inhibitor reach its target, and does cellular biology change in response? In the adipocytes studied, 5-Amino-1MQ reduced the NNMT reaction marker 1-MNA. At certain tested concentrations, NAD+ and SAM increased, and less lipid accumulation was observed during adipocyte development. Together, these findings link target inhibition with downstream metabolic changes. Neelakantan et al., 2018
Target selectivity was also examined. Under their respective assay conditions, the comparison enzymes COMT, DNMT1, PRMT3, NAMPT, and SIRT1 were not inhibited to a relevant extent. This supports selective activity within the enzyme panel tested. It reflects testing of specific comparison targets, not a complete survey of every cellular protein. Neelakantan et al., 2018
Why should such results be viewed positively? A coherent research programme needs several observations that fit together. First, the target enzyme’s activity should change. Then, matching metabolic changes become relevant. Finally, the question is whether those changes lead to an effect in tissue or a whole organism. The cell findings provide building blocks for that chain.
Their value is not that they answer every later question. They show which mechanisms can be pursued in a targeted way. A positive finding in a well-described cell model is real experimental evidence for that model and a sound reason for further study.
What was observed in mice for body weight and adipose tissue?
The often-cited 2018 study examined male mice with diet-induced obesity. After 16 weeks on a high-fat diet, nine animals per group received 5-Amino-1MQ or a control solution for eleven days. The treated animals lost an average of about 2.0 grams, or 5.1% of baseline body weight, while the control group gained an average of about 0.6 grams. Neelakantan et al., 2018
The epididymal white-fat depot examined at the end was also about 35% lighter than in the control group. Adipocytes measured there were smaller, and total plasma cholesterol was about 30% lower. The 35% figure refers to this specific fat depot, not to a measured loss of 35% of total body fat. Food intake was not statistically significantly different between groups. Neelakantan et al., 2018
The interesting pattern is the direction of several measures: body weight, adipose tissue, and a blood marker changed favourably. Comparable food intake is consistent with a metabolic-effect hypothesis. On its own, however, it does not establish which mechanism caused the weight trajectory.
As a short study with small groups, this work provides a preclinical proof of concept. Its strength is the controlled comparison. The productive question for further research is under which conditions the finding can be reproduced and how durable the changes remain.
Which additional metabolic findings add to the picture?
A 2022 study combined NNMT inhibition with a switch to a low-fat diet. Treated mice lost more weight and fat mass than mice receiving the dietary change alone. The study also found a distinct gut-microbiota pattern. It therefore extends the question to interactions among diet, metabolism, and the microbiome. The observed associations did not establish whether microbiome changes were causes or consequences of the other effects. Dimet-Wiley et al., 2022
A 2024 paper adds relevant metabolic endpoints. In mice with diet-induced obesity, 5A1MQ limited further weight and fat gain. The authors also reported improved glucose tolerance and insulin sensitivity, along with more favourable findings for fatty liver. They examined distribution of the compound in metabolically active tissues as well. The abstract describes a 28-day treatment period. Babula et al., 2024
The precise wording matters here: limiting further gain is a different endpoint from falling below baseline weight. Both may be scientifically informative. Keeping them distinct makes it easier to see what each study contributes to the overall picture.
Together, these studies support examining NNMT inhibition beyond body weight alone. Tissue quality, insulin action, and interactions among organs also become relevant. Several publications come from a connected research environment, however. Their findings advance the approach but are not automatically independent replications of the same observation.
Why is 5-Amino-1MQ also of interest in muscle research?
A second line of research concerns regeneration in ageing muscle. A 2019 paper studied 24-month-old mice after a deliberately induced muscle injury. NNMT inhibition was associated with greater muscle-stem-cell activity and larger regenerating muscle fibres. Peak torque measured in the injured tibialis anterior was about 70% higher than in control animals. Neelakantan et al., 2019
The combination of a tissue finding and a functional measurement is particularly informative. Larger muscle fibres alone do not answer whether a muscle performs better. An additional functional test can help place the biological significance of the tissue finding in context. This study examined recovery in an injured, aged muscle, which creates a specific regeneration hypothesis.
Another 2024 study followed aged mice for eight weeks with NNMT inhibition, exercise training, or both. The authors reported improvements in grip strength, while peak plantar-flexor torque did not change significantly. This shows why muscle function must be measured carefully: a favourable result in one task does not automatically mean that every performance measure improves. Dimet-Wiley et al., 2024
This opens an interesting perspective on age-related tissue function. The question is whether changes in cellular metabolism can influence the capacity to adapt and repair. The appeal of this approach lies in linking mechanism, structure, and function, rather than in a blanket promise of muscle gain or rejuvenation.
What can be learned from the different genetic models?
A target enzyme can be studied in different ways. A small-molecule inhibitor changes its activity; knockdown reduces its production, and knockout disables the corresponding gene. These interventions differ in duration, strength, and spatial effect. It is therefore informative to consider their findings together while keeping them separate.
The 2014 work by Kraus and colleagues strengthened the NNMT hypothesis because reduced expression in adipose tissue and liver was associated with protection from diet-induced obesity. Kraus et al., 2014
A later study by Brachs and colleagues showed a more differentiated picture: weight, fat mass, and insulin sensitivity changed differently according to sex, diet, and intervention. Glucose tolerance did not improve in knockout mice. In the accompanying human observational component, NNMT expression rose in adipose-tissue samples during weight reduction while circulating 1-MNA declined. Brachs et al., 2019
These differences make the research question more precise. For example, enzyme activity in tissue and the concentration of a metabolic product in blood can convey different information. A single blood marker does not necessarily describe what is happening in every organ.
A constructive interpretation is therefore that NNMT is an interesting target with context-dependent effects. Such findings help select suitable models, measurements, and later study questions. They are neither a blanket refutation of the approach nor confirmation of every conceivable use of 5-Amino-1MQ.
What is known about absorption and half-life?
For a metabolic mechanism to be relevant in an organism, the compound must reach its intended site of action. Pharmacokinetic studies therefore ask how much of a compound becomes measurable in blood, how long it remains there, and how it distributes.
An analytical study published in 2021 reported oral bioavailability of 38.4% for 5-Amino-1MQ in rats. The mean terminal half-life was 3.80 hours after intravenous administration and 6.90 hours after oral administration. These values were measured with a validated LC-MS/MS method. Awosemo et al., 2021
For development of a research approach, such data are useful because they make exposure measurable and support planning of further experiments. The two half-lives also show why a compound should not be described with a single, context-free hourly value. Species and route of administration are part of the number.
The term “bioavailability” also answers a specific question. It describes systemic availability in the experimental setting, not the strength of a desired effect. Likewise, a terminal half-life is not the same as the duration of a biological effect.
The published rat data are therefore a positive building block for preclinical development. Human absorption, tissue distribution, and elimination remain separate research questions. Animal findings cannot establish a reliable administration interval for humans.
How does this approach differ from NMN, NR, and mitochondrial peptides?
The same names often appear in discussions of cellular energy. A clear distinction by the point of intervention is still useful.
- 5-Amino-1MQ: Inhibition of the enzyme NNMT; Influences a metabolic pathway; does not supply an NAD+ building block.
- NMN and NR: Precursors for NAD+ synthesis; Supply starting materials for building NAD+.
- MOTS-c: A mitochondrially encoded signalling peptide; A different molecular approach to studying metabolic regulation.
- SS-31: Interactions at mitochondrial membranes; A membrane-focused research approach with a different target structure.
This comparison describes mechanisms, not a ranking of effectiveness. Background on the related topics is available in our guides to NAD+, MOTS-c, and SS-31.
It is also helpful to distinguish this approach from incretin agonists. The fact that two approaches are discussed in relation to weight does not mean they have the same mechanism, endpoints, or stage of development. The NNMT hypothesis acts at an enzymatic metabolic branch point. The absence of a statistically significant change in food intake in one mouse experiment should therefore not be retrospectively described as established appetite suppression.
This clear categorisation also protects the interesting profile of 5-Amino-1MQ: its research value does not require treating it as equivalent to another active compound. It can be understood as a distinct tool for studying the interplay among nicotinamide, methylation, and metabolic function. Mechanistic proximity between approaches also does not establish an added benefit from combining them.
How can the findings be interpreted positively and rigorously at the same time?
Early evidence can support a possible effect even while clinical confirmation remains outstanding. The key question is what was observed, in which model, and against which comparison. A controlled positive result in cells or animals is more than a speculation. Its scope nevertheless remains tied to the system studied.
For 5-Amino-1MQ, this leads to a clear research position: the studies assessed here provide mechanistic and preclinical evidence. Controlled human intervention data are not part of this source set. A documented ClinicalTrials.gov name search on September 20, 2026 returned no records for “5-amino-1MQ” or “5-amino-1-methylquinolinium.” Name searches also do not reliably cover every development code or registry. ClinicalTrials.gov
Interpretation also requires transparency about the research. In the 2022 microbiome paper, individual authors disclosed connections to Ridgeline Therapeutics. Independent replications, longer observation periods, and systematic safety data would strengthen the evidentiary value of the field. Study conflicts of interest
The positive outlook is therefore specific: 5-Amino-1MQ opens testable questions about metabolism and tissue function. The approach is promising where the mechanism and observed findings align. Whether these effects can be confirmed under further conditions and ultimately in humans is the next step in understanding.
Which questions about 5-Amino-1MQ are frequently asked?
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ, also written “5 Amino 1MQ,” is a small quinolinium molecule rather than an amino-acid chain. Being discussed alongside research peptides does not change that chemical classification.
Are there indications of an effect?
Yes. Cell and animal studies report biological effects, including effects on NNMT markers, adipose tissue, and muscle regeneration. These findings indicate potential in the models studied; the scale and benefit of any possible effects in humans have not yet been established.
Is 5-Amino-1MQ the same as NMN or NR?
No. NMN and NR are NAD+ precursors, whereas 5-Amino-1MQ inhibits an enzyme. The approaches touch related metabolic pathways but intervene in different ways.
Is there a scientifically established dose for humans?
The studies assessed here do not provide a validated human dose. Amounts used in animal experiments describe the respective study and cannot be directly translated into human use.
Where can readers find further information about this research compound?
The product information for 5-Amino-1MQ complements this scientific overview with information about the research material offered. The original papers linked below are the relevant sources for evaluating biological effects.
Which original studies inform this article?
- Kraus et al. (2014). NNMT knockdown and diet-induced obesity. Nature. DOI: 10.1038/nature13198
- Neelakantan et al. (2017). Structure-activity relationships of small-molecule NNMT inhibitors. Journal of Medicinal Chemistry. DOI: 10.1021/acs.jmedchem.7b00389
- Neelakantan et al. (2018). Selectivity, cellular metabolism, and diet-induced obesity in a mouse model. Biochemical Pharmacology. DOI: 10.1016/j.bcp.2017.11.007
- Neelakantan et al. (2019). Regeneration in ageing skeletal muscle. Biochemical Pharmacology. DOI: 10.1016/j.bcp.2019.02.008
- Brachs et al. (2019). Genetic NNMT deficiency and metabolic endpoints. Diabetes. DOI: 10.2337/db18-0780
- Awosemo et al. (2021). Analytical method and pharmacokinetics in rats. Journal of Pharmaceutical and Biomedical Analysis. DOI: 10.1016/j.jpba.2021.114255
- Dimet-Wiley et al. (2022). NNMT inhibition, dietary change, and the microbiome. Scientific Reports. DOI: 10.1038/s41598-021-03670-5
- Babula et al. (2024). NNMT inhibition and obesity-related metabolic impairment. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.15879
- Dimet-Wiley et al. (2024). NNMT inhibition and exercise in aged mice. Scientific Reports. DOI: 10.1038/s41598-024-66034-9
For research use only. Not for human consumption. Scientific Editorial Team: Dr. Sieglinde Klaus
References
- https://pubmed.ncbi.nlm.nih.gov/24717514/
- https://pubmed.ncbi.nlm.nih.gov/28548833/
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical pharmacology. 2018.PMID
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical pharmacology. 2019.PMID
- Brachs S, et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019.PMID
- https://pubmed.ncbi.nlm.nih.gov/34304009/
